Adding Pfizer and Astellas Pharma’s Xtandi to hormone therapy significantly cut the risk of prostate cancer spreading compared to hormone therapy alone, trial findings show.
Original Article: Pfizer/Astellas’ Xtandi cuts risk of prostate cancer spread
NEXT ARTICLE